Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Near-field imaging of buried conductors using transient EM signal transfer.

Scientific reports·2026
Same author

Adenosine signals an imbalance between activity and supply in privileged cells.

Trends in biochemical sciences·2026
Same author

Proliferative Kidney Disease and Viral Pathogens in Wild Brown Trout (Salmo trutta) Populations in the Czech Republic.

Journal of fish diseases·2026
Same author

Artificial intelligence in healthcare: the duty to inform patients.

Casopis lekaru ceskych·2026
Same author

Transferability of Real World Evidence to Support HTA Recommendations in Lower Income European Countries.

Health science reports·2026
Same author

WHO-5 Well-Being Index Reveal the Burden of Hidradenitis Suppurativa.

International journal of dermatology·2026

Related Experiment Video

Updated: Jul 4, 2026

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

Imidapril in heart failure.

Tomas Dolezal1

  • 1Department of Pharmacology, Charles University, Prague, Czech Republic. tomas.dolezal@lf3.cuni.cz

Journal of the Renin-Angiotensin-Aldosterone System : JRAAS
|November 10, 2006
PubMed
Summary

Imidapril, a long-acting angiotensin-converting enzyme (ACE) inhibitor, effectively treats hypertension and heart failure. It improves exercise capacity and left ventricular function, with a lower incidence of cough compared to other ACE inhibitors.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Angiotensin-converting enzyme (ACE) inhibitors are crucial for managing heart failure and related cardiovascular conditions.
  • Imidapril is a long-acting ACE inhibitor known for its conversion to active imidaprilat in the liver.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of imidapril in treating cardiovascular diseases.
  • To compare imidapril with other ACE inhibitors and beta-blockers in specific patient populations.

Main Methods:

  • Pharmacokinetic analysis of imidapril and imidaprilat.
  • Clinical trials assessing imidapril's effects on exercise capacity, cardiac function, and blood pressure in heart failure patients.
  • Comparative studies in acute myocardial infarction (MI) patients.

More Related Videos

The Intra-Aortic Balloon Pump
06:13

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

A Pacing-Controlled Procedure for the Assessment of Heart Rate-Dependent Diastolic Functions in Murine Heart Failure Models
07:49

A Pacing-Controlled Procedure for the Assessment of Heart Rate-Dependent Diastolic Functions in Murine Heart Failure Models

Published on: July 21, 2023

Related Experiment Videos

Last Updated: Jul 4, 2026

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

The Intra-Aortic Balloon Pump
06:13

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

A Pacing-Controlled Procedure for the Assessment of Heart Rate-Dependent Diastolic Functions in Murine Heart Failure Models
07:49

A Pacing-Controlled Procedure for the Assessment of Heart Rate-Dependent Diastolic Functions in Murine Heart Failure Models

Published on: July 21, 2023

Main Results:

  • Imidapril 10 mg once-daily improved exercise tolerance and reduced natriuretic peptide levels in chronic heart failure.
  • It demonstrated superior efficacy to bisoprolol in improving left ventricular ejection fraction post-MI.
  • Preliminary data suggest a lower incidence of cough with imidapril compared to captopril and enalapril.

Conclusions:

  • Imidapril is a versatile and well-tolerated ACE inhibitor for treating hypertension, chronic heart failure, acute MI, and diabetic nephropathy.
  • Its pharmacokinetic profile and clinical benefits support its use in cardiovascular disease management.